{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:57:25Z","timestamp":1791640645618,"version":"4.3.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Head and neck squamous cell carcinoma (HNSCC) is the most common type of tumor originating from the squamous epithelium of the oral cavity, oropharynx, larynx and hypopharynx. There is an urgent need to enhance therapeutic efficacy and ensure the function preservation of HNSCC treatment. This study aimed to evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in patients with resectable locally advanced HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a prospective single-center, single-arm, open-label, phase II study involving patients with locally advanced HNSCC who were treated with pembrolizumab (200 mg) plus docetaxel (50 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and cisplatin (50 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). After two cycles of the neoadjuvant chemoimmunotherapy, patients either proceeded to surgery or refused surgery and continued with chemoimmunotherapy and\/or chemoradiotherapy. The primary endpoint was the objective response rate (ORR), while the second endpoints were primary lesion complete pathologic response (pCR), progression-free survival (PFS) rate, overall survival (OS) rate and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 52 patients with HNSCC were enrolled (45 males\/7 females), with a median age of 61 years. The ORR rate was 87.8% (95% confidence interval [CI]: 75.2\u201395.4). Of the 27 patients who underwent resection, 12 (44.4%, 95% CI: 25.5\u201364.7) achieved a pCR and 15 (55.6%, 95% CI: 35.3\u201374.5) achieved an MPR. For the overall population, the PFS rates were 89.8% (95% CI: 77.2\u201395.6), 87.5% (95% CI: 74.2\u201394.2), and 72.7% (95% CI: 50.6\u201386.1), and the OS rates were 95.9% (95% CI: 84.7\u201399.0), 93.6% (95% CI: 81.5\u201397.9) and 84.9% (65.0\u201393.9), at 6 months, 12-months and 18 months, respectively. The most common adverse events were nausea\/vomiting (12.2%), fatigue (10.2%), rash (8.2%), neurotoxicity (8.2%) and aminotransferases elevation (8.2%). Grades 3 and 4 adverse events occurred in 12 (24.5%) and 2 (4.1%) patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pembrolizumab plus docetaxel and cisplatin reveals encouraging survival benefit with a manageable safety profile in patients with HNSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1664892","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:20:41Z","timestamp":1765948841000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy102","article-title":"Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions","volume":"29","author":"Haddad","year":"2018","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell deathligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27401","article-title":"Influence of time between surgery and adjuvant radiotherapy on prognosis for patients with head and neck squamous cell carcinoma: A systematic review","volume":"45","author":"Sun","year":"2023","journal-title":"Head Neck"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7802","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group","volume":"31","author":"Blanchard","year":"2013","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00668","article-title":"The evolving role of taxanes in combination with cetuximab for the treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: Evidence, advantages, and future directions","volume":"9","author":"Guigay","year":"2019","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27005","article-title":"Immunotherapy for the treatment of perineural spread in cutaneous head and neck squamous cell carcinoma: Time to rethink treatment paradigms","volume":"44","author":"Nightingale","year":"2022","journal-title":"Head Neck"},{"key":"B16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hed.27202","article-title":"American Head and Neck Society position statement on the use of PD-1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma","volume":"45","author":"Schmalbach","year":"2023","journal-title":"Head Neck"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12885-021-08373-8","article-title":"Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13046-022-02510-2","article-title":"Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): an open label, single-arm, phase Ib clinical trial","volume":"41","author":"Huang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/cancers15030801","article-title":"The quality of life in surgically treated head and neck basal cell carcinoma patients: A comprehensive review","volume":"15","author":"Stundys","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12070-019-01620-2","article-title":"Quality of life in head and neck cancer patients","volume":"71","author":"Sharma","year":"2019","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2014.01.015","article-title":"Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review","volume":"50","author":"Klein","year":"2014","journal-title":"Oral Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"105634","DOI":"10.1016\/j.oraloncology.2021.105634","article-title":"Pembrolizumab plus docetaxel for the treatment of recurrent\/metastatic head and neck cancer: A prospective phase I\/II study","volume":"124","author":"Fuereder","year":"2022","journal-title":"Oral Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00076-0","article-title":"Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis","volume":"22","author":"Petit","year":"2021","journal-title":"Lancet Oncol"},{"key":"B30","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2025","journal-title":"Lancet Oncol"},{"key":"B31","year":"","journal-title":"GORTEC announces new trial success for head and neck cancer treatment"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1664892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:20:41Z","timestamp":1765948841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1664892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2025.1664892"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1664892","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1664892"}}